China’s healthcare sector is booming and while the patent system has developed considerably in recent years, pharmaceutical companies should still think carefully about how to protect their rights.
Following the court’s Abraxis decision, life sciences face a more restrictive interpretation of which products qualify for supplementary protection certificates.
With China emerging as a crucial market for the life sciences, it is crucial that those in the industry keep up with the swift pace of IP reforms and other changes – especially when it comes to enforcement.
A*STAR’s head of IP and corporate services Suresh Sachi sets out his approach to partnering with biopharma innovators, the exclusivity-related stumbling blocks – and how to overcome them
Increased R&D outsourcing and patent licensing account for pharma’s diminishing representation among the world’s top 100 innovators, while technological diversification may also be playing its part
SPC disputes, second medical use issues, pharma UPC strategies, CRISPR and much more from IAM’s third annual pharma and biotech IP conference, which took place in London earlier this week
Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.
America’s life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely